{"id":"W2622249265","doi":"10.1200/jco.2017.35.15_suppl.1038","title":"Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Letrozole; Clinical endpoint; Progression-free survival; Internal medicine; Interim analysis; Breast cancer; Cancer; Oncology; Gynecology; Surgery; Clinical trial; Chemotherapy; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00338252,0.0009344581,0.001308975,0.0003864213,0.0002879776,0.0008787112,0.0007115134,0.0006322216,0.007334708],"category_scores_gemma":[0.002596754,0.0003022406,0.001589743,0.0004704565,0.000227135,0.0005707116,0.0004351141,0.001738779,0.001074807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006788549,"about_ca_system_score_gemma":0.001030918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001023454,"about_ca_topic_score_gemma":0.00523995,"domain_scores_codex":[0.9990669,0.0004591843,0.00007594188,0.00009013892,0.0001772033,0.0001305962],"domain_scores_gemma":[0.9985265,0.0004077563,0.0004444862,0.0001327603,0.0001767436,0.0003117338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.67086,0.006841563,0.01866821,0.003141709,0.007920523,0.000445956,0.0003030594,0.003346345,0.03005741,0.000484264,0.05492869,0.2030022],"study_design_scores_gemma":[0.4120259,0.2325609,0.2084318,0.0005977744,0.02112269,0.001905734,0.0001592543,0.002320063,0.01156833,0.001190408,0.1079369,0.000180186],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8193738,0.02892101,0.002884794,0.004189072,0.0007848501,0.005666984,0.1132848,0.0005844298,0.02431025],"genre_scores_gemma":[0.8665417,0.007186489,0.003162093,0.004037966,0.0005851384,0.004832141,0.09894804,0.0001393076,0.01456724],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007334708,"threshold_uncertainty_score":0.02453703,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07992102643971791,"score_gpt":0.4703164477870385,"score_spread":0.3903954213473206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}